- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04514575
Plasma Transfusion in Major Vascular Surgery
Plasma Transfusion in Major Vascular Surgery: a Danish Nationwide Registry Study
BACKGROUND
- Major blood loss is frequent in open repair of ruptured and intact abdominal aortic aneurysm (AAA) as well as in aorto-bifurcated prosthesis insertion due to aortoiliac occlusive disease.
- Major blood loss is associated with death, post-operative complications and coagulopathy.
- Data from randomized trials in trauma patients indicate that a high plasma to red blood cell (RBC) transfusion ratio reduces 30-day mortality.
- No randomized trial data are available for the AAA population.
- Observational data demonstrate, that a high plasma:RBC transfusion ratio associates to a lower 30 day mortality. However, the reports are based on small cohorts of 78-165 patients, short term outcomes and lack information on major adverse events such as cardiac and respiratory.
- The Danish Vascular Registry (DVR), covering 1996-2018, contains data on approx. 4,400 ruptured and 8,200 intact (elective/symptomatic) AAA repairs, and 5,400 open aortoiliac repairs due to occlusive disease. Expected total count 1997-2018: 17,000.
- The Danish Transfusion Database (DTDB), covering approx. 1997-2018, contains information on units of RBCs, plasma and platelets transfused. A unique patient identification number (CPR) allows merging of all data set.
OBJECTIVE
To identify whether resuscitation with a high plasma to RBC ratio associates to improves survival in open abdominal aortic surgery as compared to a low plasma to RBC-ratio.
PICO
- Population: Open abdominal aortic surgery
- Intervention: "High FFP": FFP to RBC unit ratio of 2:3 to 3:3 (0.7 - 1.0)
- Comparison: "Low FFP": FFP to RBC unit ratio of 0:3 to 1:3 (0.0 - 0.3)
- Outcome: All-cause mortality 90 days following surgery.
DATA SOURCES
CPR, Danish Civil Registration System. DNPR, Danish National Patient registry. DVR, Danish Vascular registry. DPDB, The Danish national Prescription DataBase.
Study Overview
Status
Intervention / Treatment
Detailed Description
STATISTICAL ANALYSIS PLAN
The primary analysis will be a stratified cox regression model.
STRATIFICATION:
- type of surgery/condition (ruptured AAA vs intact AAA vs aorto-iliac occlusive disease, source: DVR)
- sex (CPR)
- Center (Rigshospitalet vs. Gentofte vs. Slagelse vs. Odense vs. Kolding vs. Aarhus vs. Viborg vs. Aalborg, source: DVR)
COVARIATE ADJUSTMENT:
- calendar time (DVR)
- age (CPR)
- Carlsons comorbidity index score (DNPR)
- Priority (Acute vs. Sub-acute vs. Elective, source: DVR)
Use of anti-thrombotic drugs (DPDB). A covariate of 4 levels (ATC code is noted in parenthesis).
- None vs.
Anti-platelet therapy
- acetylsalicylic acid (B01AC06) or
- dipyridamole (B01AC07, eg. persantin or asasantin)
Anti-platelet therapy "thienopyridines-like drugs"
- clopidogrel (B01AC04) or
- ticagrelor (B01AC24, eg. Brilique) or
- prasugrel (B01AC22, eg. Efient) Comment: patients prescribed thienopyridines in combination with aspirin will be included in this "thienopyridine anti-platelet group 3"
Anti-coagulant therapy
- Vitamin K antagonists (B01AA, eg. warfarin or phenprocoumon)
- Low-molecular weight heparine (B01AB01-10)
- Direct thrombin inhibitors (B01AE, eg. Pradaxa/Dabigatran)
- Direct factor Xa inhibitors (B01AF, eg. Rivaroxaban/Xarelto). Comment: patients prescribed both anticoagulant- and antiplatelet therapy and will be included in this "Anti-coagulant group 4".
ADDITIONAL ANALYSES:
Stratify the population into 4 groups according to the total transfusion requirement
- patients receiving 10 units or less of any blood product < 24 hrs or 11-15 units < 48 hrs.vs.
- patients receiving 11-15 units of any blood product < 24 hrs. or 16-20 units < 48 hrs. vs.
- patients receiving 16-20 units of any blood product < 24 hrs. or 21-25 units < 48 hrs. vs.
- patients receiving more than 20 units of any blood product < 24 hrs. or more than 25 units < 48 hrs.
- Outcome predicted by a joint function (general interaction) of total plasma transfusion and total blood cell transfusion will be assessed in an exploratory way by inspection and by agnostic modelling in the mold of Multivariate Adaptive Regression Splines (MARS) and recursive partitioning, i.e. Classification And Regression Trees (CART).
- Redefine intervention and control group as 4th and 1st quartile of FFP:RBC ratio. Initially, the population will be divide into 4 groups according to quartiles and compared the population below 1st quartile with the population above the 4th quartile, which will define the low vs. the high FFP group, resp. However, to allow for stratification for operation type (ruptured AAA vs. intact AAA vs. occlusive disease) it may be necessary to adjust the percentile cut to retain power in the analyses. For instance, the population may be cut according to tertiles, or, if there is sufficient data, cut by quintiles (5 groups) or deciles (10 groups).
- Confine the population to patient with blood loss above 50 % of total blood volume (calculated by Naddler's equation accounting for sex, weight and height). If height and weight are not available, the registered blood loss must exceed 2 L in females and 2.5 L in males.
- Adjusting exclusively for calendar year, sex, age, Charlson's comorbidity index score, and center (ie, excluding priority and antithrombotic therapy).
MISSING DATA
Missing data will not be an issue for the number of blood transfusions because units of blood products transfused are used as an inclusion criterion. All remaining covariates are discrete, and missing data for each of those will be included as separate parameters (factor level).
STATISTICAL SIGNIFICANCE LEVEL
Bonferroni adjustment of the significance level will be applied to control for multiple testing.
With one primary and four secondary outcomes, only a P-value below 0.01 (0.05/5) will be considered statistically significant. A P-value between 0.01 and 0.05 will be considered borderline significant.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Region Zealand
-
Slagelse, Region Zealand, Denmark, 4200
- Slagelse Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
In Denmark, every citizen is registered with a unique identification number in the Civil Registration System. Patients undergoing major open abdominal aortic surgery (above 40 and below 100 years of age) registered in the Danish Vascular Registry in the period between January 1st 1997 and December 31st 2018 will be identified and linked to national health registers by using the unique identification number. The DTDB will provide data on blood transfusions. The DNPR will provide data on complications by ICD10 code and on hospital admission duration.
Data sources CPR, Danish Civil Registration System. DNPR, Danish National Patient registry. DVR, Danish Vascular registry. DPDB, The Danish national Prescription DataBase.
Description
Inclusion Criteria:
Open abdominal aortic repair with the insertion of prosthesis for either
- intact (elective or symptomatic) AAA
- ruptured AAA
- aorto-iliac occlusive disease
- Requiring massive transfusion defined as 10 units or more of any blood product(*) transfused on the same date (source DTDB)
(*) = Allogeneic packed RBCs, FFP, cryoprecipitate, or platelets. Cryoprecipitate will account for 4 units of FFP in the FFP:RBC ratio.
Exclusion Criteria:
- Surgery time limited to < 50 minutes (DVR)
- No prosthesis inserted (DVR) AND operation date (DVR) equal to the death date (CPR)
Excluding patients with surgery time less than 50 minutes or cases where no prosthesis has been inserted is expected to minimize survival bias from patients exsanguinating in the operation theater before blood products can be delivered. Intentionally, it may also exclude cases where surgery was considered futile and halted.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
High-FFP
Patients transfused with an FFP:RBC ratio of 2:3 to 3:3 (0.7 - 1.0)
|
Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
|
Low-FFP
Patients transfused with an FFP:RBC ratio at or below 1:3 (0.0 - 0.3).
|
Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
90-day survival
Time Frame: First 90 days after index surgery
|
Survival data. Source: CPR
|
First 90 days after index surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30-day survival
Time Frame: First 30 days after index surgery
|
Survival data. Source: CPR
|
First 30 days after index surgery
|
1-year survival
Time Frame: 1 year after index surgery
|
Survival data. Source: CPR
|
1 year after index surgery
|
Death or any major adverse events at 90-days
Time Frame: First 90 days after index surgery
|
Dichotomous outcome. Source: DNPR and DVR. A. Major adverse cardiovascular events "MACE" [ICD10-codes]
B. Major adverse respiratory events
C. Major adverse vascular event
D. Other
|
First 90 days after index surgery
|
Number of days alive outside hospital within 90 days
Time Frame: Day 90 after index surgery
|
Count data.
Source: DNPR and CPR
|
Day 90 after index surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Ole Pedersen, MD, PhD, Department of Clinical Immunology, Naestved Hospital, Denmark.
Publications and helpful links
General Publications
- Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, Cohen MJ, Cotton BA, Fabian TC, Inaba K, Kerby JD, Muskat P, O'Keeffe T, Rizoli S, Robinson BR, Scalea TM, Schreiber MA, Stein DM, Weinberg JA, Callum JL, Hess JR, Matijevic N, Miller CN, Pittet JF, Hoyt DB, Pearson GD, Leroux B, van Belle G; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015 Feb 3;313(5):471-82. doi: 10.1001/jama.2015.12.
- Desborough M, Sandu R, Brunskill SJ, Doree C, Trivella M, Montedori A, Abraha I, Stanworth S. Fresh frozen plasma for cardiovascular surgery. Cochrane Database Syst Rev. 2015 Jul 14;2015(7):CD007614. doi: 10.1002/14651858.CD007614.pub2.
- Johansson PI, Stensballe J, Rosenberg I, Hilslov TL, Jorgensen L, Secher NH. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion. 2007 Apr;47(4):593-8. doi: 10.1111/j.1537-2995.2007.01160.x.
- Mell MW, O'Neil AS, Callcut RA, Acher CW, Hoch JR, Tefera G, Turnipseed WD. Effect of early plasma transfusion on mortality in patients with ruptured abdominal aortic aneurysm. Surgery. 2010 Nov;148(5):955-62. doi: 10.1016/j.surg.2010.02.002. Epub 2010 Apr 7.
- Mesar T, Larentzakis A, Dzik W, Chang Y, Velmahos G, Yeh DD. Association Between Ratio of Fresh Frozen Plasma to Red Blood Cells During Massive Transfusion and Survival Among Patients Without Traumatic Injury. JAMA Surg. 2017 Jun 1;152(6):574-580. doi: 10.1001/jamasurg.2017.0098.
- Montan C, Hammar U, Wikman A, Berlin E, Malmstedt J, Holst J, Wahlgren CM. Massive Blood Transfusion in Patients with Ruptured Abdominal Aortic Aneurysm. Eur J Vasc Endovasc Surg. 2016 Nov;52(5):597-603. doi: 10.1016/j.ejvs.2016.07.023. Epub 2016 Sep 4.
- Sperry JL, Guyette FX, Adams PW. Prehospital Plasma during Air Medical Transport in Trauma Patients. N Engl J Med. 2018 Nov 1;379(18):1783. doi: 10.1056/NEJMc1811315. No abstract available.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REG-144-2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arterial Occlusive Diseases
-
Meshalkin Research Institute of Pathology of CirculationCompletedARTERIAL OCCLUSIVE DISEASERussian Federation
-
Hull University Teaching Hospitals NHS TrustWithdrawnPeripheral Arterial Occlusive DiseaseUnited Kingdom
-
Yonsei UniversityCompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
W.L.Gore & AssociatesTerminatedPeripheral Arterial Occlusive DiseaseUnited States
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, France, Germany, Italy, Switzerland, Belgium, United Kingdom
-
Medical Scientific Fund of the Mayor of ViennaCompletedPeripheral Arterial Occlusive DiseaseAustria
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, Finland
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, Switzerland
-
Ryazan State Medical UniversityRecruitingPeripheral Arterial Occlusive DiseaseRussian Federation
-
B. Braun Melsungen AGActive, not recruitingPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Plasma transfusion
-
Direction Centrale du Service de Santé des ArméesUniversity Hospital, GrenobleTerminated
-
Chandra DuggiralaUnknown
-
Inova Health Care ServicesTerminatedCovid-19United States
-
Novacescu AlexandruUniversity of Medicine and Pharmacy "Victor Babes" TimisoaraCompletedAcute Respiratory Distress Syndrome | COVID-19 Pneumonia | COVID-19 Respiratory Infection | Acute Respiratory FailureRomania
-
Rutgers, The State University of New JerseyJohns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI); University... and other collaboratorsCompletedHemorrhage | Blood Coagulation DisordersUnited States
-
Mayo ClinicCompletedSurgical Procedures, Minimally Invasive | Blood Coagulation, DisordersUnited States
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
Assistance Publique - Hôpitaux de ParisEtablissement Français du SangCompleted
-
University of Colorado, DenverCompletedLiver DiseaseUnited States
-
University of L'AquilaTRIB s.r.l.Completed